tirzepatide patent expiration In weight loss battle, Novo and Lilly face growing offensive from licensed copies Mounjaro patent expiration – Republican Administration Maintains Exclusivity Stance

Patient autonomy & plan choice Mochi: Shared decision-making with a provider on the specific GLP-1 path (including compounded options when appropriate), with room to adjust over time

What constitutes unresponsive: Clinically, per manufacture, a patient should not be considered as unresponsive to therapy until less than 5% weight loss over the course of 3 months of GLP1/GIP medication at prescribed dose has been established

Category: ENDOCRINOLOGY

There is no shortage-based exception available for it, because the precondition for that exception, an approved drug in shortage, never existed

Over time, this can support steady and sustainable weight loss when combined with healthy lifestyle changes